Acute Respiratory Distress Syndrome Treatment market size was USD 2948.8 Million in 2022: Cognitive Market Research

Acute Respiratory Distress Syndrome Treatment market size was USD 2948.8 Million in 2022: Cognitive Market Research

Introduction of Acute Respiratory Distress Syndrome Treatment Market

ARDS is a medical condition where the lungs cannot effectively absorb enough oxygen and provide it to essential organs. This happens because fluid builds up in the alveoli, which hinders the lungs from fully filling with air, resulting in less oxygen reaching the bloodstream. The global market for treating acute respiratory distress syndrome has experienced significant growth due to increased investments in research by both government and private organizations.?

These developments empower businesses to offer better-tailored solutions and services, which, in turn, contribute to the growth of the ARDS Treatment industry.?

  • On April 26, 2022, Direct Biologics, a biotechnology company specializing in regenerative medicine, shared that the FDA approved the company's approval to move forward with its Phase 3 clinical trial for ExoFlo. ExoFlo is an experimental drug that utilizes the company's pioneering extracellular vesicle (EV) platform technology to address Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19. Direct Biologics is the sole EV company to have obtained FDA Phase 3 approval for an Investigational New Drug (IND) indication thus far.

Key Insights from Acute Respiratory Distress Syndrome Treatment Market Report

The Global Acute Respiratory Distress Syndrome Treatment market size was USD 2948.8 Million in 2022. Acute Respiratory Distress Syndrome Treatment Industry's Compound Annual Growth Rate will be 5.90% from 2023 to 2030.

To know more about The Acute Respiratory Distress Syndrome Treatment Market statistics click here

What are the Prime Drivers Influencing the Growth of the Acute Respiratory Distress Syndrome Treatment Market?

  • Rising Need for ARDS Treatment to Provide Viable Market Output

The demand for ARDS treatment arises from an uptick in hospital and critical care unit admissions, driving the market's growth. According to a study titled "Acute respiratory distress syndrome readmissions: A countrywide cross-sectional analysis of epidemiology and costs of care in January 2022, 18.4% of patients with acute respiratory distress syndrome required re-hospitalization. Moreover, data from the Australian Institute of Health and Welfare, published in May 2022, reveals 11.8 million hospital admissions in 2020–21, marking a 6.3% increase from 2019–20. Among these admissions, 7.0% involved an ICU stay, 3.8% were related to respiratory disease, and 10.3% resulted in the patient passing away in the hospital.

  • On May 10, 2021, Medtronic plc, a worldwide leader in medical technology, declared the official introduction of their SonarMed airway monitoring system in the United States. This innovative device, which is unparalleled in its field, employs acoustic technology to immediately detect potential blockages and ensure the correct positioning of endotracheal tubes (ETT). By providing real-time data, the SonarMed airway monitoring system equips healthcare professionals with crucial information necessary to make well-informed, life-saving judgments when caring for their tiniest patients

Key Factors that Hinder the Growth of the Acute Respiratory Distress Syndrome Treatment Market

  • Increasing Cost of Treatment Therapeuticsto Hinder Market Growth

Several factors drive the cost of treatment rectifiers in the ARDS treatment request; developing new treatments for ARDS is a complex and precious process. It can take numerous times and millions of bones to bring a new treatment to market. Limited vacuity of payment in numerous countries, there's limited payment for ARDS treatments. This can make it difficult for cases to pierce the care they need. The cost of hospitalization for ARDS can be high due to the need for ferocious care and other technical services. There are presently no general druthers to the most effective treatments for ARDS. This means that cases have to pay the full price for these treatments. The added cost of treatment rectifiers is a major challenge for the ARDS treatment request. It can make it delicate for cases to pierce the care they need and limit the development of new treatments.

Impact Of COVID-19 on the Acute Respiratory Distress Syndrome Treatment Market

The ARDS treatment market has been greatly affected by the COVID-19 pandemic. The virus can induce a severe and potentially lethal condition called acute respiratory distress syndrome (ARDS), which predominantly targets the lungs. Consequently, there has been a notable increase in the occurrences of ARDS among individuals infected with COVID-19. This has led to a substantial increase in the demand for ARDS treatments, including mechanical ventilation and ECMO. Furthermore, the pandemic has spurred intensified research and development activities to discover new treatment options for ARDS. Consequently, the ARDS treatment market is expected to experience substantial growth in the coming years. The increased demand for ARDS treatments is primarily driven by the rising number of individuals diagnosed with ARDS due to COVID-19. In summary, the COVID-19 pandemic has profoundly impacted the ARDS treatment market, which is anticipated to expand significantly in the coming years due to the growing number of ARDS cases and advancements in treatment research.

Top Companies Market Share in Acute Respiratory Distress Syndrome Treatment Industry:

罗氏公司 , 拜耳医药保健 , SUN PHARMA , 诺华 , Fisher & Paykel Healthcare , LivaNova , Besmed , Eakin Respiratory , 辉瑞 , WEINMANN , Terumo Medical Corporation , Getinge , Eurosets , and Others

Get free sample pages of the latest published Acute Respiratory Distress Syndrome Treatment Market Report

Acute Respiratory Distress Syndrome Treatment Industry News

  • January 2022: Veru Inc., a cutting-edge clinical biopharmaceutical company focused on developing new drugs for treating breast cancer, SARS-CoV-2 and other ARDS-related diseases, has announced an FDA-aligned vision for developing Phase 3 clinical trials.
  • July 2022:Roche announced that it had launched a rapid vaccine test for SARS-CoV-2 in the market that has accepted the CE marking. The launch is SD Biosensor Inc., with which Roche has a global distribution agreement. Carried out in collaboration with.

Acute Respiratory Distress Syndrome Treatment Market Analysis:

By Drug Class, the Steroids and Antibiotics Segment Dominate the Acute Respiratory Distress Syndrome Treatment Market

According to Cognitive Market Research, steroids and antibiotics, members dominated the Acute Respiratory Distress Syndrome( ARDS) Treatment Market in 2022. Steroids and antibiotics effectively treat the underpinning causes of ARDS, similar to pneumonia and sepsis. Steroids and antibiotics are extensively available and affordable. Steroids and antibiotics have a well-established safety profile, making them a good choice for treating ARDS.?

The nitric oxide segment is the fastest-growing member of the ARDS Treatment Market. Nitric oxide is effective in perfecting lung function in cases with ARDS. Nitric oxide is fairly safe, with many side effects. Nitric oxide is a fairly new treatment for ARDS, and there's still much exploration of its effectiveness.

  • Vasoconstrictors
  • Bronchodilators
  • Steroids and Antibiotics
  • Nitric Oxide
  • Sedatives & Paralytics
  • Surfactant

Route of Administration:

  • Oral
  • Injection
  • Inhalation

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

North America Acute Respiratory Distress Syndrome Treatment Market is anticipated to hold the largest market share!

According to Cognitive Market Research, North America is anticipated to maintain its dominance during the cast period owing to recent technological advancements and the vacuity of multitudinous slice-edge pharmacological motes to ameliorate the remedial process. The prevalence of rising complaint conditions dominates the North American acute respiratory torture pattern due to major request players, increased product blessings, a developed healthcare system, and a high frequency of acute respiratory torture pattern. The United States is the dominant country in North America in the Acute Respiratory Distress Syndrome (ARDS) Treatment Market. This is because the United States has a large population of patients with ARDS due to the high prevalence of chronic diseases such as pneumonia and sepsis. The United States has a strong pharmaceutical industry, which is home to many of the leading ARDS treatment drug manufacturers.

Asia-Pacific is anticipated to grow fastest from 2022 to 2030 due to an increase in biotechnology exploration and center activity. The Asia-Pacific region has a growing population, leading to increased frequency of chronic conditions like pneumonia and sepsis, which are the leading causes of ARDS. The Asia-Pacific region is passing rapid-fire profitable growth, leading to increased healthcare expenditure. This creates a favorable terrain for developing and relinquishing new ARDS treatment drugs. There's adding mindfulness of ARDS in Asia-Pacific due to the sweats of patient advocacy groups and healthcare professionals. This is leading to further cases being diagnosed and treated for ARDS.

Frequently Asked Questions (FAQs)

What is the market size for the ARDS Treatment market in 2022?

  • The global market size for the ARDS Treatment market 2022 was 2948.8 USD billion.

What is the growth rate for the ARDS Treatment market during the forecast period?

  • The global market is expected to grow with a CAGR of 5.90% during the forecast period.

Which is the leading region of the market for ARDS Treatment?

  • North America had the largest global ARDS Treatment market revenue share in 2022.

Which region is expected to witness the fastest growth in the coming years?

  • Asia Pacific to witness the fastest growth in the global ARDS Treatment market over the coming years.

Which will be the leading country in the ARDS Treatment market in 2022?

  • United States had the largest global ARDS Treatment market revenue share in 2022.

What are the key drivers for the growth of the ARDS Treatment market?

  • The main drivers of the growth of the ARDS Treatment market are Increased Demand for Diagnosis, Rising need for ARDS treatment, and More Product Launches.

Which is the major segment in the ARDS Treatment market by Route of Administration?

  • The Injection segment had the largest share in the global market by component.

Which is the major segment in the ARDS Treatment market by Distribution Channel?

  • In 2022, the Hospital Pharmacies segment had a major revenue share in the global market in terms of service.

Contact Us

Nicolas Shaw

Cognitive Market Research

20 N State Street, Chicago,

Illinois, 60602

United States

USA: +1 312-376-8303

Europe and UK: (+44) 20-8144-9523

Asia Pacific: (+852) 81930785

Email: [email protected]

Website: https://www.cognitivemarketresearch.com/about-us

About Cognitive Market Research Company:

Cognitive Market Research has evolved as one leading market research and consulting firm and it provides services across multiple domains. Cognitive Market Research gathers and analyzes data about customers, competitors, distributors, and other market actors and forces operational across the value chain. As a market research company, we follow a complete process of gathering information about the target market and end-use industries to verify the complete journey of the product or service in the global market. It helps our readers understand the demand and viability of their product/service and how it might perform in the real world and helps them to build business strategies accordingly.

要查看或添加评论,请登录

社区洞察

其他会员也浏览了